Efficacy of different second- and third-generation assays for detection of hepatitis C virus antibodies in plasma and sera also tested by polymerase chain reaction

Serodiagnosis and Immunotherapy in Infectious Disease Pub Date : 1995-06-01 DOI:10.1016/0888-0786(95)95344-P

F.H Pujol , L Blitz-Dorfman , G León , F Monsalve , J.M Echevarría , F Liprandi

{"title":"Efficacy of different second- and third-generation assays for detection of hepatitis C virus antibodies in plasma and sera also tested by polymerase chain reaction","authors":"F.H Pujol , L Blitz-Dorfman , G León , F Monsalve , J.M Echevarría , F Liprandi","doi":"10.1016/0888-0786(95)95344-P","DOIUrl":null,"url":null,"abstract":"<div><p>Sera or plasma from 52 blood donors, initially reactive by Ortho HCV EIA 2.0 were tested by other immunoassays (Abbott HCV EIA, UBI HCV EIA and Innotest HCV EIA). Positivity was confirmed by confirmatory assays (RIBA 2.0 or RIBA 3.0 and Inno-LIA or Inno-LIA III); hepatitis C virus (HCV) RNA was detected by reverse transcription nested polymerase chain reaction (RT-nested PCR). Forty-four (84.6%) were repeatedly positive by Ortho, 41 (78.8%) by Abbot, 37 (71.2%) by Innotest and 36 (69.2%) by UBI. When tested for RIBA 2.0, 35 (67.3%) were positive. Only 26 sera (50%) were positive for HCV RNA. None of the Innotest or UBI negative sera were positive for HCV RNA nor for confirmatory tests. UBI and Innotest seem more reliable for detection of antibodies against HCV, and combined application of anti-HCV immunoblot assay and HCV RNA detection by PCR is required for confirmation of HCV infection.</p></div>","PeriodicalId":101161,"journal":{"name":"Serodiagnosis and Immunotherapy in Infectious Disease","volume":"7 2","pages":"Pages 51-54"},"PeriodicalIF":0.0000,"publicationDate":"1995-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0888-0786(95)95344-P","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Serodiagnosis and Immunotherapy in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/088807869595344P","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Sera or plasma from 52 blood donors, initially reactive by Ortho HCV EIA 2.0 were tested by other immunoassays (Abbott HCV EIA, UBI HCV EIA and Innotest HCV EIA). Positivity was confirmed by confirmatory assays (RIBA 2.0 or RIBA 3.0 and Inno-LIA or Inno-LIA III); hepatitis C virus (HCV) RNA was detected by reverse transcription nested polymerase chain reaction (RT-nested PCR). Forty-four (84.6%) were repeatedly positive by Ortho, 41 (78.8%) by Abbot, 37 (71.2%) by Innotest and 36 (69.2%) by UBI. When tested for RIBA 2.0, 35 (67.3%) were positive. Only 26 sera (50%) were positive for HCV RNA. None of the Innotest or UBI negative sera were positive for HCV RNA nor for confirmatory tests. UBI and Innotest seem more reliable for detection of antibodies against HCV, and combined application of anti-HCV immunoblot assay and HCV RNA detection by PCR is required for confirmation of HCV infection.

查看原文本刊更多论文

采用聚合酶链反应对不同的第二代和第三代丙型肝炎病毒抗体检测方法在血浆和血清中的有效性进行了测试

对52名献血者的血清或血浆进行其他免疫测定(雅培HCV EIA、UBI HCV EIA和Innotest HCV EIA)，这些献血者最初通过Ortho HCV EIA 2.0反应。通过验证性试验(RIBA 2.0或RIBA 3.0和innoi - lia或innoi - lia III)确认阳性;采用逆转录巢式聚合酶链反应(rt -巢式PCR)检测丙型肝炎病毒(HCV) RNA。Ortho重复阳性44例(84.6%)，Abbot重复阳性41例(78.8%)，Innotest重复阳性37例(71.2%)，UBI重复阳性36例(69.2%)。riba2.0检测阳性35例(67.3%)。只有26份(50%)血清HCV RNA阳性。Innotest或UBI阴性血清中HCV RNA和确认试验均未呈阳性。UBI和Innotest对HCV抗体的检测似乎更可靠，需要联合应用抗HCV免疫印迹法和PCR检测HCV RNA来确认HCV感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Serodiagnosis and Immunotherapy in Infectious Disease

自引率

0.00%

发文量